Analystreport

CRISPR Therapeutics (NASDAQ:CRSP) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $70.00 price target on the stock.

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time